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Abstract 
Background: Many factors influence breast cancer progression, including the ability of 
progenitor cells to sustain or increase net tumour cell numbers. Our aim was to define 
whether alterations in putative progenitor populations could predict clinicopathological 
factors of prognostic importance for cancer progression.   
Methods: Primary cultures were established from human breast tumour and adjacent non-
tumour tissue. Putative progenitor cell populations were isolated based on co-expression or 
concomitant absence of the epithelial and myoepithelial markers EPCAM and CALLA 
respectively.  
Results: Significant reductions in cellular senescence were observed in tumour versus non-
tumour cultures, accompanied by a stepwise increase in proliferation:senescence ratios. A 
novel correlation between tumour aggressiveness and an imbalance of putative progenitor 
subpopulations was also observed. Specifically, an increased double-negative (DN) to 
double-positive (DP) ratio distinguished aggressive tumours of high grade, estrogen 
receptor-negativity or HER2-positivity. The DN:DP ratio was also higher in malignant 
MDA-MB-231 cells relative to non-tumourogenic MCF-10A cells. Ultrastructural analysis 
of the DN subpopulation in an invasive tumour culture revealed enrichment in lipofuscin 
bodies, markers of ageing or senescent cells.  
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Conclusions: Our results suggest that an imbalance in tumour progenitor subpopulations 
imbalances the functional relationship between proliferation and senescence, creating a 
microenvironment favouring tumour progression. 
 
Background 
Breast cancer is a heterogeneous disease of considerable social and economic burden. 
Significant interest surrounds the question whether cancer stem/progenitor cells drive 
tumour formation [1, 2], however it remains to be understood if progenitor analysis has 
prognostic value in cancer patients. One approach towards interrogating this involves using 
patient tumour primary cultures to correlate in vitro data and clinicopathological 
information. 
 
Breast progenitor cells are isolated based on expression of markers suggesting capabilities 
to generate cells of mixed myoepithelial and luminal epithelial lineages [3], [4]. Other 
methods involve isolation of cells positive for aldehyde dehydrogenase (ALDH) activity 
[5], or ultrastructural identification [6]. Importantly, primary breast cultures retain 
progenitor/stem cell populations [7]. 
 
Using primary cultures from human breast tumour and non-tumour tissue, we sought to 
define correlations between progenitor cell numbers and clinicopathological or functional 
indicators of cancer aggressiveness. Our results demonstrate an imbalance between two 
putative progenitor cell populations in clinicopathologically-aggressive tumours, in 
conjunction with functional alterations promoting increased proliferation or reduced growth 
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arrest. Taken together, full investigations of progenitor populations in relation to 
clinicopathological parameters could make an important contribution towards a better 
understanding of breast cancer progression. 
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Methods 
Reagents 
Suppliers: trypsin-EDTA, penicillin/streptomycin, penicillin/streptomycin/neomycin, 
fungizone, Cyquant, X-gal, Alexa-Fluor antibodies (Invitrogen); soybean trypsin inhibitor, 
collagenase I, hyaluronidase 1-S, DMEM/Ham’s F12, bovine insulin, peroxidase-labelled 
secondary antibodies (Sigma); HMEC, mammary epithelial growth medium (MEGM) kits, 
foetal bovine serum (FBS, Lonza); glutaraldehyde (Fluka); osmium tetroxide (Electron 
Microscopy Services). Antibody suppliers: actin, ESA and SMA (Sigma); cytokeratin-19, 
PE-conjugated CALLA, FITC-conjugated EPCAM, FITC- or PE-conjugated IgG controls 
(Dako); cytokeratin-18 (Abcam); cytokeratin-14 (Millipore); vimentin and p63 (BD 
Biosciences).  
 
Primary cultures 
Breast primary cultures were generated from patient lumpectomy/mastectomy samples with 
informed consent as approved by the Medical Ethics committees of Beaumont Hospital and 
the Mater Misericordiae Hospital, in accordance with the Declaration of Helsinki. One 
piece each of tumour tissue and non-tumour margins (Additional file 1) were cultured as 
described [8]. Tissues were incubated in 10X penicillin/streptomycin/neomycin, minced in 
DMEM/F12 containing 1X penicillin/streptomycin/neomycin, 10% FBS, 10µg/ml insulin, 
5µg/ml fungizone, 100U/ml hyaluronidase 1-S, 200U/ml collagenase and rotated for 2 
hours/37°C. Supernatants were pelleted, washed and cultured in MEGM. Occasional 
fibroblast contamination was removed by brief trypsinization (to remove fibroblasts but not 
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underlying epithelial cells), and cultures containing >30% fibroblasts were discarded. In 
some experiments, primary human mammary epithelial cells (HMEC, Lonza) were cultured 
in MEGM. 
 
Breast cell lines 
MCF10A and MDA-MB-231 cells (ATCC) grown normally in  DMEM-F12, 5% horse 
serum, 0.5µg/ml hydrocortisone, 10µg/ml insulin, 100ng/ml cholera toxin, 20ng/ml human 
recombinant EGF (MCF10A) or DMEM, 10% FBS, 2mM L-glutamine(MDA-MB-231) 
were conditioned in MEGM for 2-3 weeks and used in flow cytometry experiments as 
controls for normal and tumourogenic phenotypes respectively. 
 
Proliferation assays 
Primary cells (5x103) were plated in triplicate and harvested after 0, 3 or 6 days. Cyquant 
solution was incubated on freeze-thawed cells (5 min), and emitted fluorescence detected at 
520nm on a Wallac plate-reader. Fluorescence readings of unknown samples were 
translated into cell numbers by referring to two separate fluorescence standard curves – one 
for non-tumour and one for tumour cultures- constructed from known cell numbers 
(Additional file 2). The slope of each proliferation graph was calculated from the linear 
regression line using the formula y=mx+c, where m=slope and c=y-intercept. 
 
Senescence-associated β-galactosidase assays 
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Primary cells (5x104) were plated in duplicate, and stained for senescence-associated β-
galactosidase activity [9]. Three brightfield micrographs per condition were captured, and 
blue senescent cells expressed as a percentage of total cells/field. 
 
Immunofluorescence staining for epithelial and myoepithelial markers 
Primary cells (passage 1-2) grown in chamber slides were fixed in 3.7% paraformaldehyde 
and immunostained for epithelial (K19, K18, ESA) or myoepithelial (SMA, K14, VIM) 
markers using DAPI as a nuclear counter-stain. Primary antibodies were omitted in 
negative controls, and slides visualized on a Zeiss LSM510-meta confocal microscope. 
 
SDS-PAGE and Western blotting 
Confluent primary cultures were harvested in RIPA (20mM Tris-HCl pH7.5, 150mM NaCl, 
5mM EDTA, 1% Triton-X100) containing protease and phosphatase inhibitors. Lysates 
were dounced and 25µg supernatant subjected to SDS-PAGE and Western blot analysis for 
K19, K18, VIM and p63. 
 
FACS analysis of putative progenitor cell populations 
Confluent passage 0 primary cells (T25 flask/condition) were trypsinized, blocked in 
human serum and co-incubated with FITC-conjugated mouse anti-human EPCAM and PE-
conjugated mouse anti-human CALLA (4ºC/30 min). Negative controls were unlabelled or 
single-stained with FITC-EPCAM, PE-CALLA, FITC-IgG or PE-IgG. Cells were analyzed 
on a Beckman Coulter Cyan-ADP and/or an Accuri-C6 flow cytometer. Cells were sorted 
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into CALLA+/EPCAM+, CALLA+/EPCAM-, CALLA-/EPCAM- or CALLA-/EPCAM+ 
populations on a BD FACSAria cell sorter. Some passage 0 cells were analyzed for activity 
of the stem cell marker ALDH by Aldefluor assay [5]. Briefly, 2x105 cells were 
resuspended in assay buffer and incubated with activated substrate or the negative control 
reagent before analysis. 
 
Transmission electron microscopy (TEM) 
Passage 0 primary cultures or HMECs were fixed with 2.5% glutaraldehyde, processed as 
described [10] and analyzed on a FEI-Tecnai transmission electron microscope. TEM was 
also performed on sorted DN subpopulations expanded in 24-well plates. 
 
Calculations and statistics 
Data are expressed as mean ± standard error of the mean. Non-tumour versus tumour 
results were compared using non-parametric tests and one-tailed unpaired t-tests. 
Population variances were first compared using Instat-3.3.6 to inform the choice of 
equal/unequal variance between populations. The proliferation:senescence ratio was 
calculated based upon the data shown in Fig. 2B - the linear regression slopes of 
proliferation graphs and the percentages of senescent cells at the timepoint measured. 
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Results 
Primary breast cultures recapitulate the cellular balance of human breast.  
Primary cultures of both non-tumour (NT) and tumour (T) human breast tissue yielded 
adherent organoids with outwardly-proliferating colonies (Fig. 1A, left). Two cellular 
populations were observed - large polygonal cells in colony centres (lpc; Fig. 1A, right), 
and small polygonal cells (spc) at the peripheries. Since spc and lpc resembled respectively 
myoepithelial and luminal epithelial cells, expression of epithelial and myoepithelial 
markers was examined by immunofluorescence microscopy (Fig. 1B). In comparison to the 
negative control (-ve), cultures were mostly dual-positive for epithelial markers such as 
K18, K19 or epithelial-specific antigen (ESA) and myoepithelial markers such as K14, 
vimentin or smooth muscle actin (SMA). Western blot (Fig. 1C) detection of K18 was not 
as sensitive as immufluorescence analysis, since only some of the cultures expressed K18. 
Interestingly our analysis (Fig. 1C) also revealed that 3 out of 4 non-tumour cultures 
expressed high levels of the epithelial marker K19 and low levels of the myoepithelial 
marker p63. In contrast, 3 out of 4 tumour cultures expressed low levels of K19 but high 
levels of p63. Western blotting analysis also confirmed high expression of the 
myoepithelial marker vimentin. 
 
Ultrastructural and functional properties of breast primary cultures separate non-tumour 
and tumour primary cultures.  
Ultrastructural analysis of matched cultures was undertaken to confirm differences between 
tumour and non-tumour specimens (Fig. 2). Firstly, tumour cells were considerably larger 
than non-tumour cells (~100µm versus 16µm respectively along widest axis, data not 
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shown). Extensive abnormal vesiculation patterns were identified in the peri-nuclear 
regions of tumour versus non-tumour cultures (Fig. 2A, VNT versus VT). Multi-nucleation 
of tumour cells was frequently observed, in parallel with compromised nuclear membranes 
(Fig. 2A, NMNT versus NMT). Furthermore, tumour cell mitochondria were abnormal, 
elongated and occasionally fused (Fig. 2A, MNT versus MT). Finally, non-tumour cells 
displayed a well-differentiated rough endoplasmic reticulum (RER) while that in tumour 
cells was fragmented and dispersed (Fig. 2A, RNT versus RT).  
 
We next investigated if morphological differences were accompanied by cell fate 
differences (Fig. 2B). Proliferation abilities were assessed by Cyquant assay on 4 non-
tumour cultures and 12 tumour cultures – 5 low grade (LG, grade 1-2) and 7 high grade 
(HG, grade 3). Values were calculated relative to a standard curve of fluorescence intensity 
versus known cell numbers (Additional file 2). A significant increase in proliferation was 
observed in high grade tumour cultures (HG; grade 3) relative to non-tumour or low grade 
tumour cultures (LG; grades 1-2; Fig. 2B, left). Since Cyquant proliferation assays quantify 
all cells rather than just actively-proliferating cells, we performed senescence-associated 
(SA) β-galactosidase assays [9] to estimate growth arrest (Fig. 2B, right). Non-tumour 
cultures had two-fold higher SA-β-galactosidase staining than that in tumour cultures. This 
was independent of the grade of the originating tumour, and did not reflect an impaired 
capacity to senesce in response to exogenous stimulation (data not shown). 
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As the balance between proliferation and senescence is more important than either 
parameter alone, we examined whether altered proliferation:senescence ratios in breast 
primary cultures could identify aggressive tumours. The proliferation:senescence 
relationship was estimated based on proliferation graph slopes and senescence values (Fig. 
2B). Our data revealed a stepwise increase in proliferation:senescence ratio from non-
tumour through LG and finally HG tumours, correlating with a simple model of tumour 
progression  (Table 1). 
 
Alterations in putative progenitor cell subpopulations correlate with aggressive tumours 
Since progenitor cells control the generation of new cells in a tissue, we questioned if 
alterations in progenitor populations could distinguish between aggressive and non-
aggressive tumours. Several pieces of evidence suggested the presence of progenitors in 
primary cultures. Firstly, tumour and non-tumour cultures exhibited epithelial and 
myoepithelial co-differentiation (Fig. 1). Secondly, they expressed the myoepithelial 
marker p63 (Fig. 1C) which is also a progenitor marker [11]. Thirdly, filter-grown cultures 
had basal electron-lucent, glycogen-rich cells (Fig. 3a arrow) resembling those described 
as progenitor/stem cells in mammary duct basal laminae [6]. Apically-located cells were 
attenuated and squamous-differentiated (Fig. 3b, top arrow). Layering of dark filament-
rich cells (Fig. 3b arrows) with light glycogen-rich cells (Fig. 3b arrowhead) was observed 
in all cultures (Fig. 3c). 
 
Flow cytometry was used to isolate putative progenitor populations from primary cultures 
and search for links with clinicopathological evidence of tumour progression. Non-tumour 
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and tumour cultures were analyzed for expression of CALLA (myoepithelial) and EPCAM 
(epithelial) markers [4, 12]. All cultures had highest expression of CALLA and lowest 
expression of EPCAM single-positive cells, with double-negative (DN) populations 
exceeding double-positive (DP). Results were grouped according to clinicopathological 
factors of prognostic relevance, namely tumour grade and expression of ER and HER2 
(Fig. 4A). The DP population was significantly reduced in aggressive HG relative to LG 
tumour or non-tumour cultures (p<0.05), while the CALLA population increased 
significantly. Both DN and EPCAM populations decreased slightly with increasing grade. 
Trends were similar in aggressive ER-negative tumour cultures, but not statistically 
significant. Interestingly, the DN population was increased in aggressive HER2-positive 
relative to HER2-negative tumours, resembling the larger DN profile of non-tumour cells. 
 
Given DN differences in aggressive HG or ER-negative tumours versus aggressive HER2-
positive tumours, we performed ultrastructural analysis on DN populations from one non-
tumour and one tumour culture (grade 2 IDC, ER+, HER2+). Although both populations 
had many similarities (data not shown), unique to the tumour DN population was the 
presence of abundant lipofuscin bodies (Fig. 4B, arrows). These markers of cellular ageing 
were also observed in unsorted normal and pre-invasive tumour cultures (data not shown). 
 
Since both DN and DP populations are putative progenitor/stem cells [3, 4], we questioned 
whether population ratios better reflected tumour progression than changes in single 
populations (Fig. 4C). Increased DN:DP ratios were observed in all aggressive tumour 
cultures (HG, ER- or HER2+) relative to non-tumour or non-aggressive tumour cultures. A 
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DN:DP increase was also noted in metastatic MDA-MB-231 cells versus normal MCF-10A 
cells (Fig. 4D). For these experiments, MDA-MB-231 and MCF-10A cells were switched 
from their normal media and conditioned to grow in MEGM (as used for primary cultures). 
Although this was not their preferred medium, the cells grew well and we did not observe 
any morphological differences as a result of media switching (Additional file 3). We also 
analyzed ALDH activity to estimate progenitor cell numbers. A low percentage of cells 
were ALDH-positive (Fig. 4E, left). However ALDH activity in LG tumour cultures was 
significantly higher than that in non-tumour cultures (Fig. 4E, right). Interestingly, ALDH 
activity dropped significantly from LG to HG cultures, to lower than that in non-tumour 
cultures (p<0.001). This mirrored observed reductions in both DP and DN populations in 
HG versus LG tumour cultures (Fig. 4A).  
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Discussion 
Intriguing recent work has suggested that immunohistochemical profiling of breast tumours 
for cancer stem cell populations may have prognostic value [13]. To probe at a cellular 
level the relationship between progenitor cells and clinicopathological indicators of breast 
cancer progression, we isolated primary cells from tumour and non-tumour tissue and 
cultured them in serum-free medium [14]. Although many isolation methods and media 
formulations have been described over the years, we chose this method because it allowed 
us a high yield of cells from small tissue samples and because the commercially-available 
medium offered advantages of consistency and reproducibility relative to self-made 
medium. Using these culture conditions, most cultures presented two cell-type populations 
as described [7, 15, 16], namely large and small polygonal cells which are presumptive 
epithelial and myoepithelial cells respectively. A relatively crude isolation approach which 
allows retention of multiple cellular populations may offer advantages over isolation 
approaches in which cells are purified to homogeneity, since a mixed cell population better 
recapitulates the cellular balance of tumours in vivo. 
 
Myoepithelial marker expression was found to dominate over luminal epithelial expression, 
consistent with observations in HMEC [17, 18]. Expression studies have linked 
myoepithelial and mesenchymal/basal-like phenotypes; the latter associated with poor 
patient prognosis [19]. While some studies favour separate media formulations [20], our 
ultrastructural data suggested that MEGM supported separate growth of non-tumour and 
tumour populations. For example, malignant characteristics including abnormal 
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vesiculation, branched mitochondria, poorly-developed RER and multi-nucleation were 
observed only in tumour cultures.  
 
Mesenchymal/basal-like phenotypes also promote progenitor growth and tissue 
regeneration [21]. The expression of the myoepithelial marker p63 was recently described 
to be involved in the development of stratified epithelial tissue such as that of the breast, 
and it has been associated with the presence of progenitor cells and tumour progression 
[11].  Interestingly, most of our non-tumour cultures expressed the luminal epithelial 
marker K19, but low levels of the myoepithelial (and progenitor) marker p63, while tumour 
cultures conversely expressed low levels of K19 and high levels of p63. These data may 
suggest that non-tumour cultures are enriched in more differentiated cells (K19-positive) 
than tumour cultures which may be less differentiated and more enriched in multipotent or 
non-specialized cells (p63-positive) [22]. While K14/K18 are generic markers for 
discerning epithelial versus myoepithelial cells, K19/p63 are considered to discriminate 
more differentiated/specialized cells versus non differentiated/specialized cells [11, 18, 23]. 
In addition, CALLA/EPCAM have been described to better detect progenitor populations 
[12]. In fact, we used CALLA and EPCAM as myoepithelial and epithelial markers to 
subdivide cultures into terminally-differentiated or undifferentiated (putative progenitor) 
populations. Both populations, double positive (DP) and double-negative (DN) for these 
markers have been described as putative progenitor cells [3, 4]. Our cultures had large DN 
populations and highest expression of myoepithelial markers, in accordance with other 
reports [12]. 
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We sought to correlate subpopulation changes with tumour clinicopathological parameters, 
and observed decreased DP populations in aggressive tumours of high grade or ER 
negativity. ALDH activity was also reduced in HG tumours, an interesting fact since 
ALDH expression has been correlated with poor prognosis in breast cancer [5, 24] – 
although the opposite has been reported in ovarian cancer [25]. However we did observe 
increased ALDH activity in LG tumours relative to non-tumour cultures. Taken together, 
our results could suggest that DP, DN and ALDH-positive populations are progenitor cells 
lost from aggressive HG or ER-negative tumours. Perhaps such progenitor cells generate 
fully-differentiated cells in normal tissue, and their loss could favour undifferentiated 
phenotypes in aggressive tumours. The DN population was also lower in aggressive HG or 
ER-negative tumours, but not in aggressive HER2-positive tumours. If individual cells 
over-expressing HER2 are indeed tumour-initiators [26], our DN results could represent a 
progenitor population associating with HER2 expression.  
 
DN and DP populations have been described as slightly different putative progenitor/ stem 
cell populations; with DN representing an undifferentiated population while DP represents 
a multipotent population [4, 12]. Since in normal tissue the balance between these 2 
populations is tightly regulated, we wondered if the balance is disrupted in malignant 
phenotypes and may be a marker of tumour progression. Thus in an attempt to 
mathematically reflect this balance, we calculated the ratios between DN and DP 
subpopulations. Importantly, we show that a DN/DP imbalance (in the form of increased 
DN:DP ratios) identifies all three types of aggressive tumour, namely HG, ER-negative or 
HER2-positive. The abundance of lipofuscin bodies, markers of cellular ageing, in tumour 
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DN populations is an interesting point. Since premature senescence was reduced in tumour 
versus non-tumour cultures, we speculate that tumour DN populations represent 
undifferentiated cells capable of senescing, and that DN reductions in aggressive HG or 
ER-negative tumours suggest loss of an endogenous tumour-suppressive mechanism.  
 
Interestingly, we did not observe DN reductions in HER2-positive cultures. However 
elevated HER2 can drive premature senescence [27], and high DN:DP ratios better identify 
aggressive tumours than DN changes alone. Thus loss of a putative pro-senescence (DN) 
“normal” population is unlikely to drive tumour progression unless proliferation is high. 
Any pro-senescence (anti-tumourogenic) effects of HER2 could be outweighed by the pro-
proliferative effects of HER2 [28]. Our study has illustrated a stepwise increase in 
proliferation:senescence ratios through non-tumour, LG and HG tumours. The 
proliferation:senescence balance is an important determinant of tumour progression, 
dormancy or regression. If the DN:DP ratio estimates this, it could have prognostic value. 
Although progenitor isolation using markers will never recapitulate the complexity of these 
plastic and diverse cellular populations, our study nonetheless illustrates that marker studies 
can yield important insights into clinical samples. 
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Conclusions 
We have reported reduced senescence in tumour versus non-tumour breast primary 
cultures, and stepwise increases in the proliferation:senescence ratio with increasing tumour 
grade. Isolation of putative progenitor subpopulations revealed a novel correlation between 
increased DN:DP ratios and clinicopathological indicators of aggressive tumours (HG, ER-
negativity or HER2-positivity). Our data suggest that progenitor population imbalance 
could promote tumour progression by altering the relationship between proliferation and 
senescence (Fig. 5). Future investigations relating clinicopathological factors to alterations 
in progenitor cell populations may be valuable in dissecting mechanisms associated with 
progenitor-driven breast tumour progression.  
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Abbreviations: MEGM, mammary epithelial growth medium; HMEC, human mammary 
epithelial cells; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; LC, 
lobular carcinoma; ITLC, invasive tubular lobular carcinoma; SA-β-gal, senescence-
associated β-galactosidase; ER, estrogen receptor; PR, progesterone receptor; ESA, 
epithelial-specific antigen; SMA, smooth muscle actin; VIM, vimentin; CALLA, common 
acute lymphoblastic leukaemia antigen; EPCAM, epithelial cell adhesion molecule; DP, 
CALLA & EPCAM double-positive; DN, CALLA & EPCAM double-negative; HG, high 
grade; LG, low grade; ALDH, aldehyde dehydrogenase; TEM, transmission electron 
microscopy; K14, cytokeratin-14; K18, cytokeratin-18; K19, cytokeratin-19. 
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Table 1: Increased proliferation:senescence ratios correlate with tumour progression. 
 
 Proliferation:Senescence ratio 
Non-tumour (P n=4; S n=4) 1.9 
Low-grade tumours (P n=5; S n=4) 9.5 
High-grade tumours (P n=7, S n=8) 23.8 
where P= proliferation assays, S= senescence assays. 
The ratio of proliferation:senescence was calculated for non-tumour, low grade tumour and 
high grade tumour primary cultures using the slope of proliferation graphs and senescence 
values from Fig. 2B. An increased ratio was observed in the stepwise progression from 
non-tumour to low grade tumour to high grade tumour categories. 
 
 
Figure Legends 
 
Fig. 1: Characterization of tumour and non-tumour primary cultures.  
A. Organoid-derived cultures (A, top panels, 10X magnification) from both tumour and 
non-tumour specimens had large polygonal cells (lower panels, lpc) surrounded by small 
polygonal cells (lower panels, spc, 20X magnification). B. Representative tumour and 
non-tumour cultures (passages 1-3) were analyzed for expression of the epithelial markers 
K19, K18 and ESA and the myoepithelial markers SMA, K14 and vimentin (scale bar 
50µm). C. Representative cultures were immunoblotted for expression of epithelial (K19, 
K18) and myoepithelial (vimentin, p63) markers. 
 
Fig. 2: Ultrastructural and functional differences distinguish non-tumour from 
tumour primary cultures. 
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A. TEM analysis of non-tumour cells revealed modest numbers of cytoplasmic vesicles 
(Vnt), single nuclei, distinct nuclear double membranes (NMnt), regular mitochondria (Mnt) 
and well-organized RER (Rnt). Tumour cells showed abnormal peri-nuclear vesicles (Vt), 
>1 nucleus per cell with thin nuclear membranes (NMt), abnormal mitochondria (Mt) and 
disorganized RER (Rt). B. Proliferation was enhanced in HG tumour cultures relative to 
LG tumour cultures or non-tumour cultures (left). Basal senescence, estimated by SA-β-
galactosidase staining, was lower in tumour versus non-tumour cultures (right; p<0.001). 
 
Fig. 3: Ultrastructural identification of putative progenitor cells in primary cultures. 
HMEC and tumour primary cultures analyzed by TEM were observed to grow as multi-
layers, with basally-located cells having plump morphologies (a, arrow) compared to the 
attenuated morphologies of apically-located cells. Filament-rich cells (b, arrows) were 
layered with glycogen-rich cells (b, arrowhead). A schematic representation of cellular 
organization is shown in (c). 
 
Fig. 4: Isolation of putative progenitor cells from primary cultures and cell lines. 
A. Breast primary cultures were sorted into CALLA single-positive, EPCAM single-
positive, double-positive (DP) or double-negative (DN) populations, and expressed as a 
percentage of total cells. B. TEM analysis revealed a high content of lipofuscin bodies in 
the DN population sorted from a tumour culture (arrows). C. The DN:DP ratio increased in 
three types of aggressive tumour (high grade, ER-negative or HER2-positive) relative to 
non-tumour or non-aggressive tumour cultures. D. The DN:DP ratio in metastatic MDA-
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MB-231 cells exceeded that in non-tumourogenic MCF-10A cells. E. Activity of the stem 
cell marker ALDH was similar in non-tumour versus pooled tumour cultures (left), but 
significantly higher in non-tumour and low grade tumour cultures compared to high grade 
tumour cultures (p<0.001; right). 
 
Fig. 5: Progenitor imbalance model.  
A normal phenotype likely requires a fine balance between different progenitor populations 
(DP and DN). In normal cells, a balance between proliferation and senescence interplays 
with a balance between these putative progenitor populations. This promotes regulated 
generation of differentiated cells. In aggressive tumours, increased proliferation and 
decreased senescence influences the equilibrium between different progenitor populations. 
This may alter the differentiated/undifferentiated cell balance, promoting basal-like 
phenotypes associated with tumour progression. 
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Additional files 
Additional file 1: 
Primary culture patient information. 
Format: PDF 
 
Additional file 2:  
Proliferation assay standard curves for tumour and non-tumour cultures. 
Two non-tumour and two tumour cultures were used to generate standard curves to 
calculate numbers of cells from fluorescence values obtained at different time points of the 
Cyquant proliferation assays. 
Format: PDF 
 
Additional file 3:  
MEGM medium does not alter the morphology of MCF-10A and MDA-MB-231 cells.  
 MCF-10A and MDA-MB-231 cells were cultured for 15 days in MEGM or their standard 
serum-positive media, and imaged by phase contrast microscopy. No overt morphological 
differences were observed in either cell type after the media was switched. 
Format: PDF 
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